ReviewBiosensors2026
Nucleic Acid-Based Field-Effect Transistor Biosensors.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Application of Flexible Graphene Field-Effect Transistor Sensors in Multidimensional Biosensing and Precision Medicine.Materials (Basel, Switzerland) · 2026Review
- Practical Applications of 2D Material FET Biosensors: Functionalization Strategies and Detection Performance.Biosensors · 2026Review
- Framework Nucleic Acids as a Nanocontainer for Delivering Heterogeneous Molecular Drugs.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The demand for rapid and highly sensitive sensing technologies is increasing across diverse fields, including precise disease diagnosis, early-stage screening, and real-time environmental monitoring. Field-effect transistor (FET)-based sensing platforms have shown tremendous potential for detecting target molecules at extremely low concentrations, owing to their ultrahigh sensitivity, label-free and amplification-free operation, and rapid response. In recent years, the rapid advancement of nucleic acid probe design and interfacial engineering has markedly accelerated the development of FET sensors, leading to the emergence of nucleic acid-based FET (NA-FET) biosensors. Beyond their fundamental role in nucleic acid detection, the integration of nucleic acid aptamers and framework nucleic acids has greatly expanded NA-FET biosensors' applicability to a wide range of analytes and multiplexed detection. At the same time, advances in semiconductor materials have endowed the NA-FET biosensor with highly efficient signal transduction and diverse device architectures, enabling successful proof-of-concept demonstrations for various clinically and environmentally relevant molecular biomarkers. Furthermore, the integration into portable, wearable, and implantable devices has laid a solid foundation for their future development into real-world applications. This review summarizes recent cutting-edge progress in NA-FET biosensors, highlights key design strategies and performance improvements, and discusses current challenges, future development directions, and their prospects for practical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.